델카쓰 시스템즈(DCTH) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

DCTH

Delcath Systems Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$11.96

-0.26 ▼ -2.13%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$11.82

-0.12 ▼ -1.01%

델카쓰 시스템즈(DCTH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$413M

스몰캡

P/E

1993.3

고평가 구간

배당수익률

없음

52주 위치

68%

저점 +47% · 고점 -13%

애널리스트

적극 매수

Fundamental health

vs. Medical Devices 소형주

수익성

Top 18%

성장

Top 54%

밸류에이션

Top 36%

재무 안정

Top 33%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 1년 (not other companies).

Very cheap

Cheap

Typical

Pricey

🔥 Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 752원. Over the past 1년, it usually traded around 255원. One of the priciest stretches of the past 1년.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.1 profitable years

Index ⓘ	RUT	P/E ⓘ	1993.33	EPS (ttm) ⓘ	0.01	Insider Own ⓘ	7.58%	Shs Outstand ⓘ	34.5M	Perf Week ⓘ	-5%
Market Cap ⓘ	0.41B	Forward P/E ⓘ	-	EPS next Y ⓘ	4.98%	Insider Trans ⓘ	0.21%	Shs Float ⓘ	31.9M	Perf Month ⓘ	-2.92%
Enterprise Value ⓘ	0.32B	PEG ⓘ	-	EPS next Q ⓘ	-0.09	Inst Own ⓘ	47.4%	Short Float ⓘ	8.45%	Perf Quarter ⓘ	10.33%
Income ⓘ	0.00B	P/S ⓘ	4.57	EPS this Y ⓘ	-902.86%	Inst Trans ⓘ	-3.63%	Short Ratio ⓘ	5.66	Perf Half Y ⓘ	13.58%
Sales ⓘ	0.09B	P/B ⓘ	3.66	EPS next 5Y ⓘ	-	ROA ⓘ	0.53%	Short Interest ⓘ	2.69M	Perf YTD ⓘ	18.42%
Book/sh ⓘ	3.27	P/C ⓘ	4.62	EPS past 3/5Y ⓘ	-	ROE ⓘ	0.58%	52W High ⓘ	-12.95% ($13.74)	Perf Year ⓘ	4.82%
Cash/sh ⓘ	2.59	P/FCF ⓘ	21.52	Sales past 3/5Y ⓘ	215.3% 120.21%	ROIC ⓘ	0.49%	52W Low ⓘ	47.29% ($8.12)	Perf 3Y ⓘ	169.98%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	103.31%	Gross Margin ⓘ	85.97%	Volatility(W/M) ⓘ	3.65% 4.12%	Perf 5Y ⓘ	33.33%
Dividend TTM ⓘ	-	EV/Sales ⓘ	3.59	Sales Y/Y TTM ⓘ	67.95%	Oper. Margin ⓘ	-1.79%	ATR (14) ⓘ	0.54	Perf 10Y ⓘ	-100%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	10.33	EPS Q/Q ⓘ	-209.59%	Profit Margin ⓘ	0.62%	RSI (14) ⓘ	41.73	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	11.24	Sales Q/Q ⓘ	26.33%	SMA20 ⓘ	-7.14% ($12.88)	Beta ⓘ	0.52	Target Price ⓘ	$22.5
Payout ⓘ	-	Debt/Eq ⓘ	0.01	Earnings ⓘ	2026/8/6	SMA50 ⓘ	0.05% ($11.95)	Rel Volume ⓘ	0.92	Prev Close ⓘ	$12.22
Employees ⓘ	156	LT Debt/Eq ⓘ	0.01	EPS/Sales Surpr. ⓘ	69.1% 6.34%	SMA200 ⓘ	14.42% ($10.45)	Avg Volume(3M) ⓘ	0.48M	Price ⓘ	$11.96
IPO ⓘ	2001/10/23	Option/Short ⓘ	Yes/Yes			Trades ⓘ	5168	Volume ⓘ	437,806	Change ⓘ	-2.13%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $25M (YoY +26%) · 순이익 $-1M (YoY -200%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Delcath Systems Inc (DCTH) Investment Analysis

What kind of company is Delcath Systems Inc?

델카쓰 시스템즈(DCTH) 초고성장주

Healthcare · Medical Devices

Small-Cap — Low Volume, High Volatility

🩺 Delcath Systems (DCTH) is an interventional oncology medical device company focused on the treatment of primary and metastatic liver cancer. Through its flagship products, the HEPZATO KIT and CHEMOSAT, the company provides a treatment system that delivers high-dose chemotherapy locally to the liver while controlling systemic exposure.

Learn more about Delcath Systems Inc →

Market Cap

$0.4B

Approx. KRW 0.6 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank3374

Employees156people

IPO2001/10/23

Current Price$11.96 ≈ 16,385원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-9

8월 6일 (목) · 장 시작 전

예상 매출 - · EPS $-0.09

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS +69.1% 매출 +6.3%

🔔 Earnings release 2026년 2월 26일 (목) · 장 시작 전 EPS +20.6% 매출 +0.7%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-1.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

0.6%

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices 소형주 Median -15.9% · Top 29%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

86.0%

✓ 우수

My positionTop 5%

Low range Average High range

Medical Devices 소형주 Median 57.1% · Top tier

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

0.6%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 소형주 Median -37.5% · Top 20%

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

0.5%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 소형주 Median -21.8% · Top 20%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

0.5%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 소형주 Median -25.0% · Top 21%

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.01

✓ Very low debt

My positionTop 5%

Low range Average High range

Medical Devices Median 0.39

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

11.24

✓ 우수

My positionTop 5%

Low range Average High range

Medical Devices Median 2.91

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

10.33

✓ 우수

My positionTop 5%

Low range Average High range

Medical Devices Median 2.09

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$22.50

현재가 대비 +88.1%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+5.0%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+5.9%

평균 서프라이즈

2026.05.07

상회

실적 $-0.03 · 예상 $-0.09 +68.1%

2026.02.26

하회

실적 $-0.05 · 예상 $-0.03 -56.3%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-902.9%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 소형주 Median 51.6% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+5.0%

부진

My positionBottom 25%

Low range Average High range

초고성장주 소형주 Median 33.7% · Bottom 22%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+120.2%

우수

My positionTop 5%

Low range Average High range

초고성장주 소형주 Median 32.4% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+26.3%

양호

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 14.5% · Top 39%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -35%p below the market

DCTH +33.3% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-35.0%p

Significantly behind the market

vs Health Care (XLV)

+8.8%p

slightly ahead of the sector average

1-year basis

vs S&P 500

-11.2%p

behind the market

vs Health Care (XLV)

-14.9%p

behind the sector average

Rank among peers

5-year return Top 20% Based on 34 peers

1-year return Lower-Mid (lower 45%) Based on 38 peers

Current position within 52-week range

Low (-47.3%p) High (-12.9%p)

Current price is 47.3% above the 52-week low and 12.9% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-14.9%

Annualized volatility

46.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

Current price $11.96 fell below the lower band ($12.08). Selling pressure excessive; worth watching for a short-term bounce. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 0.072 · Signal 0.255 · Hist -0.183. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 41.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 5.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Cash Flow, Pricey on Vs. Earnings, In line with peers on Vs. Assets·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Mid-range

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

1993.33x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Medical Devices median 30.60x · Bottom 1% — expensive within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

3.66x

✓ Fair

My positionMid-range

Low range Average High range

Medical Devices 소형주 median 3.15x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

4.57x

✓ Fair

My positionMid-range

Low range Average High range

Medical Devices 소형주 median 2.82x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

21.52x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Devices 소형주 median 26.43x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$22.50 vs. current price +88.1%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Medical Devices

Who owns it?

Ownership is broadly stable

Insider modest net buying +0.2% · Institutional net selling -3.6% · Short interest moderate 8.4% · Short interest fell -3.4%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

+0.2%

Insiders net buying

🏦 Institutions (funds & investors)

-3.6%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 47.4%

Moderate institutional participation

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 7.6%

Meaningful insider stake

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 45.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

8.4%

Moderate

Healthcare 소형주 Median 11.2%

Past 90 days 📉 -3.4%p decrease

Short interest days to cover

5.7 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 34.5M주

Float (tradable shares) 31.9M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding DCTH

ETFs with the highest weightings · 10 total shown

SURI

Simplify Propel Opportunities ETF

3.49%

$77M

SBIO

ALPS Medical Breakthroughs ETF

0.20%

$202M

IWC

iShares Micro-Cap ETF

0.06%

$1.4B

GSSC

Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF

0.04%

$1.0B

IWO

iShares Russell 2000 Growth ETF

0.02%

$14.3B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
DCTH This Stock	$412.9M	1993.3 ▼	3.7 ▼	0.58% ▲	-	-2.1%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 델카쓰 시스템즈(DCTH)?

델카쓰 시스템즈(DCTH) belongs to the Healthcare sector and operates in the Medical Devices industry.

What is the market cap of DCTH?

The market cap of DCTH is approximately $413M, ranking 3,374 within its sector.

What is the P/E ratio of DCTH?

DCTH has a P/E ratio of approximately 1993.3x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for DCTH?

DCTH has recorded a 52-week high of $13.74 and a low of $8.12.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.